On June 6, 2026, the 4th Ruijin Hospital International Symposium on Organ Transplantation was successfully held. Chair Professor Paul Kwong Hang Tam, Vice President of Macau University of Science and Technology(MUST), was invited to attend the symposium and delivered a special lecture entitled “Liver Regenerative Medicine” during the “International Master Forum” session.
The symposium focused on frontier areas including organ transplantation, hepatobiliary surgery, regenerative medicine, precision diagnosis and treatment, and clinical translation. It brought together experts and scholars from universities, hospitals, and research institutions in China and abroad to discuss the latest advances, key challenges, and future directions in the field of organ transplantation. The program covered a wide range of topics, including adult and pediatric liver transplantation, minimally invasive hepatobiliary surgery, liver regenerative medicine, precision therapy, infection prevention and control, xenotransplantation, and related translational research.
In his lecture, Professor Tam systematically introduced the research progress and clinical translation prospects of liver regenerative medicine, with a focus on the potential applications of regenerative medicine in liver disease repair, functional reconstruction, and support for organ transplantation. The lecture demonstrated Macau University of Science and Technology’s continued development in precision regenerative medicine, stem cell and tissue repair, and clinical translational research.
Chair Professor Paul Kwong-Hang Tam, Vice President of MUST, delivered a special lecture
Professor Tam’s participation has further strengthened academic collaboration between MUST and prominent mainland hospitals and experts in the field of organ transplantation. It also established a solid foundation for future cross-regional collaboration in fields of liver disease, regenerative medicine, and translational medicine. Looking ahead, Macau University of Science and Technology will continue to leverage its research platforms in precision regenerative medicine to promote the integration of basic research, clinical needs, and translational applications, contributing to life and health technology innovation and biomedical translation in the Guangdong-Hong Kong-Macao Greater Bay Area.
